9.52
-0.19 (-1.96%)
| Previous Close | 9.71 |
| Open | 9.63 |
| Volume | 4,388,651 |
| Avg. Volume (3M) | 6,340,854 |
| Market Cap | 1,546,257,536 |
| Price / Earnings (TTM) | 4.29 |
| Price / Sales | 1.52 |
| Price / Book | 41.92 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 |
| Profit Margin | 38.14% |
| Operating Margin (TTM) | 77.40% |
| Diluted EPS (TTM) | 2.75 |
| Quarterly Revenue Growth (YOY) | 610.30% |
| Quarterly Earnings Growth (YOY) | 179.90% |
| Current Ratio (MRQ) | 2.06 |
| Operating Cash Flow (TTM) | -189.21 M |
| Levered Free Cash Flow (TTM) | 61.88 M |
| Return on Assets (TTM) | 19.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Novavax, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.75 |
|
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 8.78% |
| % Held by Institutions | 57.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Shah Capital Management | 30 Jun 2025 | 11,511,780 |
| Park West Asset Management Llc | 31 Mar 2025 | 2,528,857 |
| Tsp Capital Management Group, Llc | 31 Mar 2025 | 1,352,165 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (B of A Securities, -26.47%) | Sell |
| Median | 6.50 (-31.72%) | |
| Low | 6.00 (Citigroup, -36.98%) | Sell |
| Average | 6.50 (-31.72%) | |
| Total | 2 Sell | |
| Avg. Price @ Call | 8.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 20 Aug 2025 | 7.00 (-26.47%) | Sell | 9.52 |
| 22 Jul 2025 | 9.00 (-5.46%) | Hold | 7.22 | |
| Citigroup | 17 Jun 2025 | 6.00 (-36.97%) | Sell | 6.49 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 21 Aug 2025 | Announcement | Novavax Announces Convertible Debt Refinancing |
| 12 Aug 2025 | CNBC | FDA may pull authorization of Pfizer's Covid vaccine for children under 5, company says |
| 06 Aug 2025 | Announcement | Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights |
| 30 Jul 2025 | Announcement | Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025 |
| 24 Jul 2025 | Announcement | Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study |
| 30 Jun 2025 | CNBC | Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot |
| 11 Jun 2025 | Announcement | Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial |
| 29 May 2025 | Announcement | Novavax to Participate in Upcoming Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |